As a part of a study that aims to evaluate and improve the labelling of containers for injectable drugs, Failure Mode and Effects Analysis (FMEA) was applied to the label reading process. Implementing a FMEA on a small-scale cognitive process involved various challenges including difficulties in representing the process, defining the failure modes, causes and effects, developing the rating scales for criticality, and rating the criticality of the failure modes. The failure modes were rated via two focus groups of healthcare professionals. The results highlight complexities and potential pitfalls with applying FMEA to the label reading process.
Get full access to this article
View all access options for this article.
References
1.
BonnabryP.CingriaL.SadeghipourF.IngH.Fonzo-ChristeC.PfisterR. E. (2005). Use of a systematic risk analysis method to improve safety in the production of paediatric parenteral nutrition solutions. Qual Saf Health Care, 14(2), 93–98.
2.
BurgmeierJ. (2002). Failure mode and effect analysis: An application in reducing risk in blood transfusion. Jt Comm J Qual Improv, 28(6), 331–339.
3.
CSA International. (1999). Labelling of Drug Ampoules, Vials, and Prefilled Syringes (Vol. CAN/CSAZ-264.2). Etobicoke, Ontario, Canada: CSA International.
4.
DeRosierJ.StalhandskeE.BagianJ. P.NudellT. (2002). Using Health Care Failure Mode and Effect Analysis™: The VA National Center for Patient Safety's Prospective Risk Analysis System. Joint Commission Journal on Quality and Patient Safety, 28(5), 248–267.
5.
EsmailR.CummingsC.DerschD.DuchschererG.GlowaJ.LiggettG.HulmeT. (2005). Using Healthcare Failure Mode and Effect Analysis tool to review the process of ordering and administrating potassium chloride and potassium phosphate. Healthc Q, 8 Spec No, 73–80.
6.
FechterR. J.BarbaJ. J. (2004). Failure mode effect analysis applied to the use of infusion pumps, San Francisco, CA, United States.
7.
HicksR. W.SantellJ. P.CousinsD. D.WilliamsR. L. (2004). MEDMARX 5th Anniversary Data Report: A Chartbook of 2003 Findings and Trends 1999–2003. Rockville, MD: USP Center for the Advancement of Patient Safety.
8.
Institute for Safe Medication Practices Canada. (2006). Failure Mode and Effects Analysis - A tool for proactively identifying risk in health care (pp. 26): Institute for Safe Medication Practices Canada.
9.
KrouwerJ. S. (2004). An improved failure mode effects analysis for hospitals. Arch Pathol Lab Med, 128(6), 663–667.
10.
LeapeL. L.BrennanT. A.LairdN.LawthersA. G.LocalioA. R.BarnesB. A.HebertL.NewhouseJ. P.WeilerP. C.HiattH. (1991). The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med, 324(6), 377–384.
11.
National Coordinating Council for Medication Error Reporting and Prevention. (2001). NCC MERP Index for Categorizing Medication Errors. Retrieved Nov. 26, 2006, from http://www.nccmerp.org/medErrorCatIndex.html
United States Pharmacopoeia. (2000). DPPR-a Final Glance (No. 75): United States Pharmacopeia.
16.
WetterneckT. B.SkibinskiK.SchroederM.RobertsT. L.CarayonP. (2004). Challenges with the Performance of Failure Mode and Effects Analysis in Healthcare Organizations: An IV Medication Administration HFMEA. Paper presented at the Human Factors and Ergonomics Society 48th Annual Meeting, New Orleans, Louisiana.
17.
ZapantaC. M.SnyderA. J.WeissW. J.ClearyT. J.ReibsonJ. D.RawhouserM. A.LewisJ. P.PierceW. S.RosenbergG. (2005). Durability testing of a completely implantable electric total artificial heart. Asaio J, 51(3), 214–223.
